A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Joaquin Mateo
No relevant relationships to disclose
Charlotte Rose Lemech
No relevant relationships to disclose
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Howard A. Burris
No relevant relationships to disclose
Yung-Jue Bang
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Joseph Paul Eder
No relevant relationships to disclose
Roy S. Herbst
No relevant relationships to disclose
Sunil Sharma
Research Funding - GlaxoSmithKline
Hyun Cheol Chung
No relevant relationships to disclose
Shaun Decordova
No relevant relationships to disclose
Karen E Swales
No relevant relationships to disclose
Michelle D Garrett
No relevant relationships to disclose
Jill I Loftiss
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael Durante
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Mark W. Russo
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Benjamin B. Suttle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Monica Motwani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Rakesh Kumar
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Johann Sebastian De Bono
No relevant relationships to disclose